EUVIMEDEUVIMED entdecken
Leserbrief

Efanesoctocog Alfa Prophylaxis in a Patient With Combined Mild Hemophilia A and Type 1 von Willebrand Disease

Destiny Uwaezuoke iD, An Pham, Jessica Garcia iD

Pediatric Blood & Cancer · 2026-01 · 73 (1)

DOI: 10.1002/pbc.32125 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 21.10.2025. Verfasst von Destiny Uwaezuoke und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Pediatrics, UT Southwestern Medical Center, Dallas, Texas, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Pediatrics, UT Southwestern Medical Center, Dallas, Texas, USA.
  • Children's Health, Dallas, Texas, USA.

ORCID-Profile: Destiny Uwaezuoke, Jessica Garcia

Zitieren

APA

Uwaezuoke, D., Pham, A., & Garcia, J. (2026). Efanesoctocog Alfa Prophylaxis in a Patient With Combined Mild Hemophilia A and Type 1 von Willebrand Disease. Pediatric Blood & Cancer, 73(1). https://doi.org/10.1002/pbc.32125

Vancouver

Uwaezuoke D, Pham A, Garcia J. Efanesoctocog Alfa Prophylaxis in a Patient With Combined Mild Hemophilia A and Type 1 von Willebrand Disease. Pediatric Blood & Cancer. 2026;73(1). doi:10.1002/pbc.32125

BibTeX
@article{Uwaezuoke2026,
  author = {Uwaezuoke, Destiny and Pham, An and Garcia, Jessica},
  title = {Efanesoctocog Alfa Prophylaxis in a Patient With Combined Mild Hemophilia A and Type 1 von Willebrand Disease},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  volume = {73},
  number = {1},
  doi = {10.1002/pbc.32125}
}
Kostenlos starten →